Cover Image
Market Research Report
Product code 
1046765

Europe Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

Published: | KBV Research | 82 Pages | Delivery time: 1-2 business days

Price

Back to Top
Europe Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
Published: November 30, 2021
KBV Research
Content info: 82 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Europe Filgrastim Market would witness market growth of 7.6% CAGR during the forecast period (2021-2027).

Filgrastim is basically a granulocyte colony-stimulating factor (GCSF) that helps in boosting the number of neutrophils in a patient's blood. This medication can help in decreasing or preventing symptoms like shortness of breath, fatigue, fever, weight loss, and chills. Doctors prescribe this medication to cure different types of cancer such as lymphoma and leukemia.

The growth of the filgrastim market is attributed to the growing prevalence of numerous diseases and the increasing geriatric population. The growing pressure on the healthcare system to reduce healthcare expenditure is estimated to propel the growth of the filgrastim market. Also, the rising demand for biosimilars in curing neutropenia among the patients would bolster the growth of the filgrastim market. In addition, several companies are increasingly investing in R&D activities for the development of better and effective biosimilars, which is estimated to spur the growth of the filgrastim market in the coming years.

The rise in the number of cancer patients is creating more demand for filgrastim in the region as it is widely given to cancer patients to boost the development of white blood cells. In addition, governments across this region have framed several healthcare policies in order to provide better healthcare facilities to the people. This strong healthcare system of the region along with the supportive reimbursement policies would augment the growth of the filgrastim market.

Moreover, the increase in the population of aged people who are more prone to diseases is one of the major factors fueling the growth of the regional market. Key market players of the region are developing innovative and effective products to fulfill the increasing requirement for filgrastim in the market. Owing to this, the growth of the regional filgrastim market would witness a surge during the forecast period.

The Germany market dominated the Europe Filgrastim Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $65.8 million by 2027. The UK market is exhibiting a CAGR of 6.6% during (2021 - 2027). Additionally, The France market is estimated to grow at a CAGR of 8.9% during (2021 - 2027).

Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksoz Group

Scope of the Study

Market Segments covered in the Report:

By Drug Type

  • Biosimilar and
  • Biologic

By Indication

  • Chemotherapy induced Neutropenia
  • Chronic Neutropenia and
  • Other Indications

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies and
  • Online Pharmacies

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Companies Profiled

  • Abbott Laboratories
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Apotex, Inc.
  • Toksoz Group

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Europe Filgrastim Market, by Drug Type
    • 1.4.2 Europe Filgrastim Market, by Indication
    • 1.4.3 Europe Filgrastim Market, by Distribution Channel
    • 1.4.4 Europe Filgrastim Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Europe Filgrastim Market by Drug Type

  • 3.1 Europe Biosimilar Market by Country
  • 3.2 Europe Biologic Market by Country

Chapter 4. Europe Filgrastim Market by Indication

  • 4.1 Europe Chemotherapy induced Neutropenia Market by Country
  • 4.2 Europe Chronic Neutropenia Market by Country
  • 4.3 Europe Other Indications Market by Country

Chapter 5. Europe Filgrastim Market by Distribution Channel

  • 5.1 Europe Hospital Pharmacies Market by Country
  • 5.2 Europe Retail Pharmacies Market by Country
  • 5.3 Europe Online Pharmacies Market by Country

Chapter 6. Europe Filgrastim Market by Country

  • 6.1 Germany Filgrastim Market
    • 6.1.1 Germany Filgrastim Market by Drug Type
    • 6.1.2 Germany Filgrastim Market by Indication
    • 6.1.3 Germany Filgrastim Market by Distribution Channel
  • 6.2 UK Filgrastim Market
    • 6.2.1 UK Filgrastim Market by Drug Type
    • 6.2.2 UK Filgrastim Market by Indication
    • 6.2.3 UK Filgrastim Market by Distribution Channel
  • 6.3 France Filgrastim Market
    • 6.3.1 France Filgrastim Market by Drug Type
    • 6.3.2 France Filgrastim Market by Indication
    • 6.3.3 France Filgrastim Market by Distribution Channel
  • 6.4 Russia Filgrastim Market
    • 6.4.1 Russia Filgrastim Market by Drug Type
    • 6.4.2 Russia Filgrastim Market by Indication
    • 6.4.3 Russia Filgrastim Market by Distribution Channel
  • 6.5 Spain Filgrastim Market
    • 6.5.1 Spain Filgrastim Market by Drug Type
    • 6.5.2 Spain Filgrastim Market by Indication
    • 6.5.3 Spain Filgrastim Market by Distribution Channel
  • 6.6 Italy Filgrastim Market
    • 6.6.1 Italy Filgrastim Market by Drug Type
    • 6.6.2 Italy Filgrastim Market by Indication
    • 6.6.3 Italy Filgrastim Market by Distribution Channel
  • 6.7 Rest of Europe Filgrastim Market
    • 6.7.1 Rest of Europe Filgrastim Market by Drug Type
    • 6.7.2 Rest of Europe Filgrastim Market by Indication
    • 6.7.3 Rest of Europe Filgrastim Market by Distribution Channel

Chapter 7. Company Profiles

  • 7.1 Abbott Laboratories
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental and Regional Analysis
    • 7.1.4 Research & Development Expense
  • 7.2 Amgen, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 Pfizer, Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Regional Analysis
    • 7.3.4 Research & Development Expense
    • 7.3.5 Recent strategies and developments:
      • 7.3.5.1 Approvals and Trials:
  • 7.4 Novartis AG
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental and Regional Analysis
    • 7.4.4 Research & Development Expense
    • 7.4.5 Recent strategies and developments:
      • 7.4.5.1 Product Launches and Product Expansions:
  • 7.5 Dr. Reddy's Laboratories Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expense
    • 7.5.5 Recent strategies and developments:
      • 7.5.5.1 Partnerships, Collaborations, and Agreements:
      • 7.5.5.2 Product Launches and Product Expansions:
  • 7.6 Teva Pharmaceutical Industries Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expenses
    • 7.6.5 Recent strategies and developments:
      • 7.6.5.1 Approvals and Trials:
  • 7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Regional Analysis
    • 7.7.4 Research & Development Expense
    • 7.7.5 Recent strategies and developments:
      • 7.7.5.1 Partnerships, Collaborations, and Agreements:
  • 7.8 Cadila Healthcare Ltd. (Zydus Cadila)
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Apotex, Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Recent strategies and developments:
      • 7.9.2.1 Product Launches and Product Expansions:
  • 7.10 Toksoz Group
    • 7.10.1 Company Overview

LIST OF TABLES

  • TABLE 1 Europe Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 2 Europe Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 3 Europe Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 4 Europe Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 5 Europe Biosimilar Market by Country, 2017 - 2020, USD Million
  • TABLE 6 Europe Biosimilar Market by Country, 2021 - 2027, USD Million
  • TABLE 7 Europe Biologic Market by Country, 2017 - 2020, USD Million
  • TABLE 8 Europe Biologic Market by Country, 2021 - 2027, USD Million
  • TABLE 9 Europe Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 10 Europe Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 11 Europe Chemotherapy induced Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 12 Europe Chemotherapy induced Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 13 Europe Chronic Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 14 Europe Chronic Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 15 Europe Other Indications Market by Country, 2017 - 2020, USD Million
  • TABLE 16 Europe Other Indications Market by Country, 2021 - 2027, USD Million
  • TABLE 17 Europe Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 18 Europe Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 19 Europe Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 20 Europe Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 21 Europe Retail Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 22 Europe Retail Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 23 Europe Online Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 24 Europe Online Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 25 Europe Filgrastim Market by Country, 2017 - 2020, USD Million
  • TABLE 26 Europe Filgrastim Market by Country, 2021 - 2027, USD Million
  • TABLE 27 Germany Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 28 Germany Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 29 Germany Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 30 Germany Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 31 Germany Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 32 Germany Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 33 Germany Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 34 Germany Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 35 UK Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 36 UK Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 37 UK Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 38 UK Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 39 UK Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 40 UK Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 41 UK Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 42 UK Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 43 France Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 44 France Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 45 France Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 46 France Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 47 France Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 48 France Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 49 France Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 50 France Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 51 Russia Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 52 Russia Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 53 Russia Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 54 Russia Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 55 Russia Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 56 Russia Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 57 Russia Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 58 Russia Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 59 Spain Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 60 Spain Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 61 Spain Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 62 Spain Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 63 Spain Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 64 Spain Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 65 Spain Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 66 Spain Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 67 Italy Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 68 Italy Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 69 Italy Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 70 Italy Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 71 Italy Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 72 Italy Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 73 Italy Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 74 Italy Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 75 Rest of Europe Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 76 Rest of Europe Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 77 Rest of Europe Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 78 Rest of Europe Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 79 Rest of Europe Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 80 Rest of Europe Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 81 Rest of Europe Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 82 Rest of Europe Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 83 Key Information - Abbott Laboratories
  • TABLE 84 Key Information - Amgen, Inc.
  • TABLE 85 Key Information - Pfizer, Inc.
  • TABLE 86 Key Information - Novartis AG
  • TABLE 87 key information - Dr. Reddy's Laboratories Ltd.
  • TABLE 88 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 89 Key Information - Kyowa Kirin Co., Ltd.
  • TABLE 90 Key Information - Cadila Healthcare Ltd.
  • TABLE 91 Key Information - Apotex, Inc.
  • TABLE 92 Key Information - Toksoz Group

List of Figures

  • FIG 1 Methodology for the research